Mutant FGF-21 Peptide Conjugate for Severe Hypertriglyceridemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for severe hypertriglyceridemia (SHTG) often fail to adequately reduce triglyceride levels, posing a risk for acute pancreatitis and cardiovascular disease.
Innovation Solution
Administration of a pharmaceutical composition containing a mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate, specifically designed with a glycosyl moiety and a 20 kDa polyethylene glycol (PEG) attached, which is administered weekly or every two weeks to achieve significant triglyceride reduction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional treatments are used for severe hypertriglyceridemia, then treatment simplicity is maintained, but triglyceride reduction efficacy is insufficient
Solution Approach 1:
The patent modifies the FGF-21 peptide through parameter changes: introducing a mutation at position 173 (T173), conjugating a glycosyl moiety, and attaching a 20 kDa PEG chain. These parameter modifications to the molecular structure dramatically enhance triglyceride reduction efficacy while maintaining a single-agent treatment approach, resolving the contradiction between treatment simplicity and efficacy.
2Quantity of substance
If FGF-21 is modified with PEG and glycosyl moiety, then triglyceride reduction efficacy is improved, but molecular structure complexity increases
Solution Approach 1:
The patent creates a composite molecular structure by combining FGF-21 peptide, glycosyl moiety, and PEG chain into a single conjugate molecule. This composite approach integrates multiple functional components that work synergistically to achieve potent triglyceride reduction while presenting as a single therapeutic agent, managing the complexity through functional integration.
Solution Approach 2:
The modified FGF-21 conjugate performs multiple functions simultaneously: the FGF-21 core provides metabolic regulation, the glycosyl moiety enhances stability and solubility, and the PEG chain extends circulation half-life. This multi-functionality within a single molecule achieves superior efficacy without requiring combination therapies.
3Reliability
If frequent administration is used, then triglyceride control is improved, but treatment frequency and patient burden increase
Solution Approach 1:
The PEGylated FGF-21 conjugate maintains continuous therapeutic action through extended circulation half-life. The 20 kDa PEG chain prevents rapid clearance, allowing the drug to maintain effective concentrations in the bloodstream and liver over extended periods, enabling reliable triglyceride control with weekly or bi-weekly dosing rather than frequent administration.
Solution Approach 2:
The patent uses lower doses of the modified FGF-21 (9-48 mg weekly) compared to what would be required with unmodified FGF-21 administered frequently. The enhanced pharmacokinetics of the PEG-glycosyl conjugate allow partial dosing at extended intervals to achieve the same or better therapeutic effect, reducing patient burden while maintaining reliability.
Data Source
AI summary
Compositions, methods and therapeutic regimens of mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugates for the treatment of severe hypertriglyceridemia are provided.